An interventional study of proState Cancer awareness education to pRomote Early screENing uptake and Control group in Anxiety, Prostate Cancer and Health Education, sponsored by Teesside University. Not yet recruiting. Open to male participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-02.
Sponsored by Teesside University · Not applicable, Interventional, and Prevention
Prostate cancer is an issue of significant public health concern. Yet in low- and middle-income countries like Nigeria, men are adversely affected due to factors including poor early prostate cancer screening uptake. Yet a gap remains in addressing this urgent problem. The proposed study seeks to pilot the feasibility and acceptability of a novel co-produced workshop intervention called "proState Cancer awareness education to pRomote Early screENing uptake (SCREEN) with men who are not or partially up to date with their screening. The SCREEN intervention is designed to raise awareness of prostate cancer, its symptoms, implications for late screening, the benefits of early screening, avenues for screening uptake, and also addressing anxiety related to screening uptake. The SCREEN intervention is low-intensity and lasts approximately two hours. The proposed study also aims to pilot and test the instrument to determine its effectiveness and cost-effectiveness, including the mechanism by which the intervention might work.
7,046 studies on the registry are indexed under Prostatic Neoplasms; 1,580 are open to participants now.
This study's planned enrollment of 74 is above the median of 60 across 5,348 interventional studies indexed under Prostatic Neoplasms.
Browse Prostatic Neoplasms studies →Teesside University is the lead sponsor of 55 studies on the registry; 10 are open to participants now.
Compared within Prostatic Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Anxiety Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
2 hour worksop session to foster awareness and encourage screening uptake
Behavioral: proState Cancer awareness education to pRomote Early screENing uptake
The control group will receive intervention as usual. This may be in the form of existing prostate cancer screening information provided in hospitals, media and health centres.
Other: Control group
The SCREEN intervention is designed to raise awareness of prostate cancer, its symptoms, implications for late screening, the benefits of early screening, avenues for screening uptake, and also addressing anxiety related to screening uptake. The SCREEN intervention is low-intensity and lasts approximately two hours.
Existing information provided by health care provider, including media around prostate cancer.
Service Satisfaction Scale
A five item scale that can be used to assess and measure satisfaction, acceptability and quality of the intervention. Higher score denote positive outcomes and acceptability. Lower score denotes poor satisfaction and acceptability.
Time frame: At the end of intervention (day 2)
Generalised Anxiety Disorder (GAD-7)
The GAD-7 is a seven item scale for screening, measuring and assessing the severity of generalised anxiety disorder. Scores of 5, 10, and 15 are taken as the cut-off points for mild, moderate and severe anxiety, respectively.
Time frame: Baseline (day 1) and at the end of intervention (day 2)]
Oslo Social Support Scale (OSSS-3)
The scale is a 3-item self-reported measure designed for assessing and measuring the level of social support. The sum score ranges from 3 to 14, with high values representing strong levels and low values representing poor levels of social support as indicated as follows: a) 3-8 poor social support, b) 9-11 moderate social support, c) 12-14 strong social support.
Time frame: Baseline (day 1) and at the end of intervention (day 2)
European Quality of Life Scale EQ-5D-5L
The EQ-5D-5L is a 5 item scale designed to aid assessment of the generic quality of life. In the EQ-5D-5L, each dimension has five response levels: no problems (Level 1); slight (Level 2); moderate (Level 3); severe (Level 4); and extreme problems (Level 5). There are 3,125 possible health states defined by combining one level from each dimension, ranging from 11111 (full health) to 55555 (worst health).
Time frame: Baseline (day 1) and at the end of intervention (day 2)
Knowledge of prostate cancer and screening scale
14 item scale that measures knowledge of Prostate Cancer (PC). The 14 items on the PC knowledge scale is scored according to whether or not the participants responded correctly to each question, and the total number of correct responses will be calculated ranging from 0 to 14, with higher scores indicating higher PC knowledge.
Time frame: Baseline (day 1) and at the end of intervention (day 2)]
Beliefs around prostate cancer and screening intention scale
A 5-item scale that measure beliefs around prostate cancer and intention to engage in screening. Score range from 0-25 with lower score denoting strong willingness to engage in early screening uptake.
Time frame: Baseline (day 1) and at the end of intervention (day 2)
Intention to test for prostate cancer scale
The scale assesses the intention to take a PSA test among men when this test is: (i) offered by a doctor or (ii) based on the men's own initiative. It also predicts which attitudes (beliefs, outcomes), subjective norms (opinions of significant others, own motivation) and perceived control (obstacles, facilitating factors) are the most important for taking a PSA test. Lower total scores mean a stronger and more determined intention to undergo prostate cancer screening. Higher scores indicate low or absent readiness to complete the test.
Time frame: Baseline (day 1) and at the end of intervention (day 2)
No study locations are listed for this record.
Plan to share: No — Data supporting this study cannot be made available due to the sensitive nature and ethical reasons on confidentiality.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Teesside University